Fixel’s neurologists and researchers are diving into groundbreaking territory with new brain targets for Deep Brain Stimulation (DBS) in dystonia treatment. While DBS is FDA-approved for targeting the subthalamic nucleus and globus pallidus internus, outcomes can vary widely between patients. This has led researchers to explore alternative targets, focusing on the basal ganglia-thalamo-cortical network and the cerebellum’s role in motor dysfunction. Emerging evidence from pre-clinical and clinical studies suggests novel targets like the cerebellum and thalamus may offer more consistent, effective results in managing dystonia symptoms. #Neurology #DBS #Dystonia #FixelInstitute #Neuroscience #UFHealth Full Study: ncbi.nlm.nih.gov/pmc/articles/pmid/39308988